Readystate Asset Management LP Regeneron Pharmaceuticals, Inc. Call Options Transaction History

Readystate Asset Management LP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1024.09 - $1201.76 $8.4 Million - $9.85 Million	8,200 Added 1366.67%	8,800 $9.25 Billion
Q2 2024 Aug 14, 2024	SELL	$883.2 - $1071.19 $9.1 Million - $11 Million	-10,300 Reduced 94.5%	600 $631 Million
Q1 2024 May 10, 2024	BUY	$902.69 - $993.35 $9.48 Million - $10.4 Million	10,500 Added 2625.0%	10,900 $10.5 Billion
Q4 2023 Feb 14, 2024	BUY	$775.18 - $881.7 $77,518 - $88,170	100 Added 33.33%	400 $351 Million
Q2 2023 Aug 14, 2023	SELL	$700.03 - $830.35 $70,003 - $83,035	-100 Reduced 25.0%	300 $216 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $272,196 - $330,788	400 New	400 $329 Million

1,531

84.1M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $79.8B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Readystate Asset Management LP, based on Form 13F filings with the SEC.

Stay updated on Readystate Asset Management LP with notifications on news.